Nemaura Medical's (NMRD) SugarBEAT® Technology Targets Billion Dollar Opportunity

Jul. 2, 2020
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their blood sugar levels as compared to a HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. SugarBEAT® can additionally be used as an adjunctive Continuous Glucose Monitoring (CGM) device by insulin users when calibrated by a finger stick reading. Visit NMRDinfo.com for more information. Please read our disclosures: https://www.redchip.com/legal/disclos...

 Read More


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market